Medical/Pharmaceuticals

Korea Zinc announces non-renewal of sulfuric acid consignment contract with Young Poong

* The consignment of sulfuric acid originated from Young Poong's Seokpo Smelter adds to the operational risks for Korea Zinc * Young Poong has passed the costs and risks associated with sulfuric acid management to Korea Zinc while backlash from the local community adds to the burden * Addit...

2024-04-16 13:48 280

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dis...

2024-04-16 08:00 726

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

* FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging * Collaboration agreement announced for joint development and commercialisation with UCSF * PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 1...

2024-04-16 06:42 639

【C.S】Cordyceps Sunshine has extended its market footprint in the world's largest traditional Chinese herbal medicine market with the introduction of their Cinnamomum product line.

TAIPEI, April 16, 2024 /PRNewswire/ -- Cordyceps Sunshine Group【C.S】Group, having recently achieved a successful U.S. IPO, hosted the '2024 China International Biomedical Innovation Development Conference and Chinese Rare Medicinal Herbs Cinnamomum Industry Transformation and Upgrade Conference' ...

2024-04-16 06:00 829

Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024

BUENOS AIRES, Argentina, April 15, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare dise...

2024-04-16 02:00 730

89th CMEF in Shanghai Elevates Global Medical Device Trade to The Next Level

SHANGHAI, April 15, 2024 /PRNewswire/ -- The 89th edition of the China International Medical Equipment Fair (CMEF) witnessed an impressive turnout of over 200,000 attendees from more than 150 countries. Prominent companies in the industry seized the opportunity to sho...

2024-04-15 21:00 847

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90% SYDNE...

2024-04-15 20:30 833

Wound Care Plus, LLC Revolutionizes Wound Management with ARANZ Medical's Silhouette Solution

CHRISTCHURCH, New Zealand, April 15, 2024 /PRNewswire/ -- Wound Care Plus, LLC, a leading provider of mobile wound care services in the US, has announced a groundbreaking partnership with ARANZ Medical to integrate ARANZ Medical's innovative Silhouette wound assessment solution into their wound c...

2024-04-15 20:00 621

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

TreeFrog Therapeutics reports on the first bioproduction of a cell therapy for Parkinson's Disease in a scalable bioreactor1 BORDEAUX, France, April 15, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is presenting for t...

2024-04-15 15:30 750

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO

SINGAPORE, April 15, 2024 /PRNewswire/ -- Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @South San Francisco[1] from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships ...

2024-04-15 14:15 764

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

– Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant – – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – – South Korea's Association of Liver Patients and Survivors and the Taiwan re...

2024-04-15 13:06 950

Bloomage Demonstrates Global Quality Management Excellence through On-Site Audit by Japan's PMDA

TOKYO, April 15, 2024 /PRNewswire/ -- Bloomage recently successfully completed the on-site Good Manufacturing Practice (GMP) audit conducted byJapan's Pharmaceuticals and Medical Devices Agency (PMDA).  As the official regulatory agency for pharmaceuticals inJapan, the PMDA holds significant resp...

2024-04-15 08:30 856

Pioneering Cutting-Edge Technologies: High-End Medical Imaging Developer VITAL HealthCare Debuts at CMEF

SHANGHAI, April 13, 2024 /PRNewswire/ -- On Apr. 11, 2024, VITAL HealthCare, one of the 5 core business divisions of the VITAL Group, marked a stunning debut at the 89th China International Medical Equipment Fair (CMEF) inShanghai. Drawing on the Group's core competence in R&D and its wealth of t...

2024-04-13 20:00 2398

【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations

NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to disc...

2024-04-12 21:00 1580

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

Second major trial for atrial shunt therapy demonstrates importance of patient selection TEWKSBURY, Mass., April 12, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave's RELIEVE-HF trial data support...

2024-04-12 13:00 1135

Healthcare Revolution 2024: Largest Industry Event Moves to Drive Superior Results in Healthcare and Medical Tourism

PALM BEACH GARDENS, Fla., April 11, 2024 /PRNewswire/ -- The largest annual gathering of key stakeholders in medical travel, healthcare leaders, and self-funded employers is back this year with an exciting new move to help stakeholders achieve superior results, elevate their programs, and redefin...

2024-04-11 23:36 1467

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

STOCKHOLM, April 11, 2024 /PRNewswire/ -- IFPA is delighted to announce the 7th IFPA Conference set to take place fromJune 27th to June 29th, 2024, in the picturesque city ofStockholm, Sweden. This year's conference promises to be a pivotal event for experts and stakeholders in the field of psori...

2024-04-11 16:00 1220

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan

HELSINKI, Finland, April 11, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform") today announced a strategic partnership whereby CBC Co., Ltd. ("CBC"), will utilize its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform's cutting-edge nanomedici...

2024-04-11 15:38 1230

Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer

SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. John Lee, MD, PhD, as its Chief Medical Office...

2024-04-11 14:59 1310

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th April poster session of the 2024 American Cancer Research Society (AACR) Annual Meeting held inSan Diego,...

2024-04-11 14:56 999
12345 ... 575